A Single-Center, Randomized, Double-Blinded, Placebo-Controlled, 4-way Cross-over Study to Assess the Effect of a Single Oral Dose of AZD3293 Administration on QTc Interval Compared to Placebo, Using Open-Label AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Subjects

Trial Profile

A Single-Center, Randomized, Double-Blinded, Placebo-Controlled, 4-way Cross-over Study to Assess the Effect of a Single Oral Dose of AZD3293 Administration on QTc Interval Compared to Placebo, Using Open-Label AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2014

At a glance

  • Drugs Lanabecestat (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Acronyms AZD3293TQT
  • Sponsors AstraZeneca
  • Most Recent Events

    • 02 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 08 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 12 Feb 2014 Status changed from not yet recruiting to recruiting according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top